Litigation Details for Sanofi-Aventis U.S. LLC v. Apotex Corp. (D. Del. 2020)
✉ Email this page to a colleague
Sanofi-Aventis U.S. LLC v. Apotex Corp. (D. Del. 2020)
| Docket | ⤷ Subscribe | Date Filed | 2020-06-12 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 10,583,110 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Sanofi-Aventis U.S. LLC v. Apotex Corp.
The small molecule drug covered by the patent cited in this case is ⤷ Subscribe .
Details for Sanofi-Aventis U.S. LLC v. Apotex Corp. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-09-09 | 107 | Claim Construction Chart | Chart for U.S. Patent Nos. 10,583,110 (“the ’110 patent”) and 10,716,777 (“the ’777 patent”). The…the ’110 patent. Exhibit B to the Joint Claim Construction Chart is a copy of the ’777 patent. Exhibit… ’110 Patent, Figs. 1-5 ’777 patent, Exhibit B, including…110 Patent at 2:43-3:41 Prosecution file history of the ’110 patent, … Prosecution file history of the ’777 patent, ’110 Patent at 8:61-65 Exhibit D | External link to document |
| 2020-11-02 | 143 | Redacted Document | Count I: Infringement of U.S. Patent No. 10,583,110 (“’110 patent”) under 35 U.S.C. § 271…IV (“’592 patent”) prostate cancer with cabazitaxel 10,583,110 …Orange Book-listed patents, including the ’170 patent and ’907 patent. Ex. 15, Patent Cert. Pursuant to…110 patent under 35 U.S.C. § 271(b); • Count III: Infringement of U.S. Patent No. …of Sanofi as to the ’170 patent, but vacated the judgment on the ’592 patent for the disclaimed claims | External link to document |
| 2020-06-12 | 4 | Patent/Trademark Report to Commissioner | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,583,110 B2. (myr) (Entered… 12 June 2020 1:20-cv-00804 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-07-31 | 62 | Amended Complaint | expiration of U.S. Patent Nos. 10,583,110 (“the ’110 patent”) and 10,716,777 (“the ’777 patent”). Case 1:20…regimen. 122. United States Patent No. 10,583,110 (copy attached as Exhibit A) is entitled…EACH DEFENDANT OF U.S. PATENT NO. 10,583,110 UNDER 35 U.S.C. § 271(e) …OF INFRINGEMENT OF U.S. PATENT NO. 10,583,110 UNDER 35 U.S.C. § 271(B) … FDA the patent number and expiration date of the ’777 patent and identified it as a patent “with respect | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
